摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-甲氧基-苯基)-丁胺 | 122875-03-0

中文名称
4-(3-甲氧基-苯基)-丁胺
中文别名
——
英文名称
4-(3-methoxy-phenyl)-butylamine
英文别名
Benzenebutanamine, 3-methoxy-;4-(3-methoxyphenyl)butan-1-amine
4-(3-甲氧基-苯基)-丁胺化学式
CAS
122875-03-0
化学式
C11H17NO
mdl
——
分子量
179.262
InChiKey
NEHQMKGFIODIOM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    35.2
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:819c68cfaa539cd1cf78492ad332dd46
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(3-甲氧基-苯基)-丁胺盐酸potassium carbonate 作用下, 以 乙腈 为溶剂, 反应 5.0h, 生成 6-Fluoro-8-{2-[4-(3-methoxy-phenyl)-butylamino]-ethoxy}-chroman-4-one
    参考文献:
    名称:
    Synthesis and Pharmacological Characterization of Novel 6-Fluorochroman Derivatives as Potential 5-HT1A Receptor Antagonists
    摘要:
    A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT1A receptor. N-2- [[(6-Fluorochroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252-1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT1A receptor, some of which were selective with respect to alpha(1)-adrenergic and D-2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolin-stimulated adenylate cyclase assays in CHO cells expressing the human 5-HT1A receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screeds and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3-benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT-induced behavioral and electrophysiological responses in rats.
    DOI:
    10.1021/jm9707840
  • 作为产物:
    描述:
    3-(3'-methoxyphenyl)-1-butyronitrile 在 lithium aluminium tetrahydride 作用下, 以 乙醚 为溶剂, 生成 4-(3-甲氧基-苯基)-丁胺
    参考文献:
    名称:
    Studies on the synthesis of 1-azaspiro[5.5]undecanes related to histrionicotoxin
    摘要:
    DOI:
    10.1021/jo00279a014
点击查看最新优质反应信息

文献信息

  • 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy
    申请人:Dupont-Passelaigue Elisabeth
    公开号:US20080167313A1
    公开(公告)日:2008-07-10
    The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R 1 and R 2 , identical or different, represent a branched or linear C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl, C 5 -C 6 cycloalkyl, nitrile, C 1 -C 4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C 1 -C 4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); YR 3 represents oxygen or NR 3 for which R 3 represents hydrogen, a linear or branched C 1 -C 7 alkyl or alkenyl radical, a C 1 -C 6 alkyl radical substituted by groups such as trifluoromethyl or phenyl (for which the phenyl ring is optionally substituted by one or more groups such as C 1 -C 4 alkoyl, C 1 -C 4 alkoxy, nitro, halogen, trifluoromethyl); Z represents an oxygen atom or a carbon atom capable of being bound to the ortho, meta or para positions of the phenyl group of formula I; n can be 0 to 5 when Z=C or 2 to 4 when Z=O; X represents oxygen or sulphur; R 4 , R 5 , R 6 , R 7 and R 8 represent hydrogen or fluorine; R 9 , R 10 and R 11 represent hydrogen or a linear or branched C 1 -C 5 alkyl group as well as the pharmaceutically acceptable base addition salts, and the various enantiomers of compounds having asymmetric carbons, and their mixtures in all proportions including in particular the racemic mixtures.
    该发明涉及一般式(I)的3,5-二氧代-(2H,4H)-1,2,4-三嗪衍生物,其中:R1和R2,相同或不同,代表分支或直链的C1-C7烷基或烯基基团,被三氟甲基、C5-C6环烷基、腈基、C1-C4烷氧羰基乙烯基、羟基羰基乙烯基、C1-C4烷氧羰基、羧酸酯、苄氧基或苯基等基团取代的C1-C6烷基基团(其中苯环可选择地被一个或多个基团如C1-C4烷酰基、C1-C4烷氧基、硝基、卤素、三氟甲基取代);YR3代表氧或NR3,其中R3代表氢、直链或分支的C1-C7烷基或烯基基团,被三氟甲基或苯基等基团取代的C1-C6烷基基团(其中苯环可选择地被一个或多个基团如C1-C4烷酰基、C1-C4烷氧基、硝基、卤素、三氟甲基取代);Z代表一氧原子或一碳原子,能够与一般式I的苯基的邻位、间位或对位结合;当Z=C时,n可以为0至5,当Z=O时,n可以为2至4;X代表氧或硫;R4、R5、R6、R7和R8代表氢或氟;R9、R10和R11代表氢或直链或分支的C1-C5烷基基团,以及药学上可接受的碱盐,以及具有不对称碳的化合物的各种对映体以及它们在所有比例中的混合物,包括特别是消旋混合物。
  • [EN] SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DERIVES SPIRO AZABICYCLIQUES SUBSTITUES EN TANT QUE MODULATEURS DE L'ACTIVITE DU RECEPTEUR DE LA CHIMIOKINE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2005080376A1
    公开(公告)日:2005-09-01
    The present application describes modulators of CCR3 of formula (Ia) and (Ib): (I) or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5', R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
    本申请描述了公式(Ia)和(Ib)的CCR3调节剂:(I)或其药用可接受的盐形式,其中Z、R1、R2、R3、R4、R5、R5'、R6、a、b、c、d和u的定义如本文所述。此外,还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病,以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
  • Heterocyclization involving benzylic C(sp<sup>3</sup>)–H functionalization enabled by visible light photoredox catalysis
    作者:Ganesh Pandey、Ramkrishna Laha、Pradip Kumar Mondal
    DOI:10.1039/c9cc04287c
    日期:——
    A general and efficient method for heterocyclization involving benzylic C(sp3)–H functionalization enabled by visible light photoredox catalysis to access a wide range of structurally diverse oxygen as well as nitrogen heterocycles up to a gram scale is reported. The potential application of this new methodology is demonstrated by the total synthesis of (−)-codonopsinine and (+)-centrolobine. Herein
    据报道,一种通用有效的杂环化方法涉及苄基C(sp 3)–H官能团,该官能团通过可见光光氧化还原催化作用可访问范围广泛的结构多样的氧和氮杂环,直至克级。(-)-codonopsinine和(+)-centrolobine的总合成证明了这种新方法的潜在应用。在本文中提出了与氟化试剂不同,selectfluor用作氧化猝灭剂和氢自由基受体。
  • Studies on histionicotoxin: rearrangement of the spirocyclic histrionicotoxin carbon skeleton into the fused pumiliotoxin skeleton
    作者:John J. Venit、Philip Magnus
    DOI:10.1016/0040-4039(80)80147-x
    日期:1980.1
    On treatment with acid the spirocyclic ketoamine 5 undergoes a retro-Mannich reaction followed by recondensation to give the unsaturated imine 8, thus converting the histrionicotoxin carbon skeleton into the pumiliotoxin C skeleton.
    在用酸处理时,螺环酮胺5进行逆曼尼希反应,然后再缩合得到不饱和亚胺8,从而将组织毒素毒素碳骨架转化为毒素毒素C骨架。
  • Enantioselective Copper-Catalyzed Remote C(sp<sup>3</sup>)–H Alkynylation of Linear Primary Sulfonamides
    作者:Cheng-Yu Wang、Zi-Yang Qin、Yu-Ling Huang、Yi-Ming Hou、Ruo-Xing Jin、Chao Li、Xi-Sheng Wang
    DOI:10.1021/acs.orglett.0c01325
    日期:2020.5.15
    The highly efficient copper-catalyzed enantioselective alkynylation of the remote C(sp3)-H bond on linear primary sulfonamides is presented here using a radical relay strategy. The chiral box-copper complex, which is used to recapture the in-situ-generated alkyl radical via a 1,5-HAT strategy, is the key to success, affording the chiral alkynes after a following reductive elimination. A general substrate
    此处使用自由基中继策略介绍了高效的铜催化线性伯磺酰胺上远程C(sp3)-H键的铜对映体选择性炔基化反应。手性盒铜配合物是成功的关键,该手性盒铜配合物可通过1,5-HAT策略重新捕获原位生成的烷基,在还原反应消除后得到手性炔烃。该方法证明了一般的底物范围,温和的条件以及出色的区域和对映选择性控制。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐